AbbVie Buy Hold or Sell Recommendation

ABBV -- USA Stock  

USD 89.95  4.45  4.71%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding AbbVie is 'Cautious Hold'. Macroaxis provides AbbVie buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AbbVie positions. The advice algorithm takes into account all of AbbVie available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from AbbVie buy-and-hold prospective. Check also AbbVie Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.

Time Horizon

Risk Tolerance

Execute Advice
Sell AbbVieBuy AbbVie
Cautious Hold


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

For the selected time horizon AbbVie has a mean deviation of 1.29, semi deviation of 0.0, standard deviation of 1.75, variance of 3.07, downside variance of 0.0 and semi variance of 0.0
Macroaxis provides buy, hold, or sell suggestion on AbbVie to complement and cross-verify current analyst consensus on AbbVie. Our buy, hold, or sell recommendation engine determines the organization potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure AbbVie is not overpriced, please confirm all AbbVie fundamentals including its Shares Outstanding, Net Income, Number of Employees, as well as the relationship between Price to Book and Book Value Per Share . Given that AbbVie has Price to Earning of 24.30 times, we suggest you validate AbbVie market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

AbbVie Thematic Classifications

Macroaxis Index IdeaMacroaxis Index
Macroaxis power theme of selected equities with solid fundamentals
Giant Impact IdeaGiant Impact
Public companies with mega capitalization

Returns Distribution Density

Mean Return0.39Value At Risk3.93
Potential Upside1.85Standard Deviation1.75
 Return Density 

AbbVie Greeks

Alpha over DOW
Beta against DOW=0.0319
Overall volatility
Information ratio =0.31

AbbVie Volatility Alert

AbbVie exhibits very low volatility with skewness of -0.94 and kurtosis of 1.0. However, we advise investors to further study AbbVie technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare AbbVie to competition

AbbVie Fundamental Vs Peers

FundamentalsAbbViePeer Average
Return On Equity149.25 % (15.17) %
Return On Asset10.49 % (15.64) %
Profit Margin21.55 % (5.50) %
Operating Margin43.56 % (10.91) %
Current Valuation182.39 B152.14 B
Shares Outstanding1.51 B1.43 B
Shares Owned by Insiders0.09 % 6.91 %
Shares Owned by Institutions71.29 % 18.37 %
Number of Shares Shorted38.44 M3.24 M
Price to Earning24.30 times40.69 times
Price to Book43.16 times14.44 times
Price to Sales4.94 times17.81 times
Revenue29.61 B9.85 B
Gross Profit21.53 B21.75 B
EBITDA12.9 B1.41 B
Net Income6.35 B517.71 M
Cash and Equivalents9.47 B3.89 B
Cash per Share5.97 times5.17 times
Total Debt37.87 B7.36 B
Current Ratio1.20 times3.30 times
Book Value Per Share2.24 times13.64 times
Cash Flow from Operations8.35 B1.25 B
Short Ratio3.32 times2.09 times
Earnings Per Share3.98 times2.30 times
Price to Earnings To Growth0.76 times1.22 times
Number of Employees29 K10.67 K
Market Capitalization146.3 B29.78 B
Total Asset53.05 B126.86 B
Retained Earnings4.38 B38.24 B
Working Capital5.42 B3.58 B
Current Asset16.31 B36.8 B
Current Liabilities10.89 B33.34 B
   Sale by Timothy Richmond of 10792 shares of AbbVie [view details]

AbbVie Alerts

Trading Alerts and Improvement Suggestions
AbbVie generates negative expected return over the last 30 days
About 71.0% of the company shares are held by institutions such as insurance companies
On July 12, 2018 AbbVie paid $ 0.96 per share dividend to its current shareholders
Latest headline from Purchase by Glenn Tilton of 5400 shares of AbbVie
Check also AbbVie Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.